ERBB2 and breast cancer: We also utilized PDX models, arguably the most relevant existing human preclinical models, to illustrate the significant effect of EZH2 methyltransferase inhibition on spontaneous metastasis in Luminal B but not HER2+ breast cancer (Fig. 7).